FindTrial
Sign In

Safety and Efficacy Study of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00290914
Enrollment
Unknown
Registered
2006-02-13
Start date
Unknown
Completion date
Unknown
Last updated
2012-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Brief summary

The purpose is to evaluate the safety and usefulness of the investigational drug, vilazodone in depression.

Interventions

DRUGVilazodone

Sponsors

Pharmacology Research Institute
Lead SponsorOTHER

Study design

Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Male or female patients 18-65 years of age, inclusive.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026